1. Scrip
  2. >>New Products

Merck & Co Expands C Diff Franchise With US Zinplava Approval

 
• By Alexandra Shimmings

Merck & Co is planning a first-quarter 2017 launch of Zinplava, its novel therapy for use in Clostridium difficile infection, following a US FDA approval, strengthening the company’s leading position in an infectious disease with great unmet need.

The US FDA has approved Merck & Co. Inc.’s Zinplava (bezlotoxumab) for reducing the recurrence of Clostridium difficile infection (CDI) in patients 18 years of age or older who are receiving antibacterial drug treatment of CDI and are at high risk for CDI recurrence.

The product is an antibody therapy targeted against a toxin produced by the bacterium, known as toxin B, that causes...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Aurobindo On Easier US Biosimilar Pathway, Zentiva Miss And Deal Strategy

 
• By Vibha Ravi

Do US FDA’s efforts at simplifying the biosimilar pathway create more competition and threaten Aurobindo Pharma's return on investments? Management speaks on this, biosimilar filing plans and deal strategy at the Q2 FY26 earnings call

Pipeline Watch: Four Approvals And Four Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Boehringer Sees Opportunities For Jascayd In Evolving China IPF Landscape

 
• By Xu Hu

Boehringer’s PDE4B inhibitor Jascayd was approved for IPF in China on Oct. 22, marking its second nod globally soon after the US. The German firm discusses with Scrip the opportunities and challenges in this market.

Akebia Abandons Non-Dialysis Trial For Vafseo On Likely Higher Costs

 
• By Manas Mishra

After yet another regulatory setback in its quest to bring Vafseo to non-dialysis dependent kidney disease patients in the US, Akebia said it would no longer conduct a planned Phase III trial for the commercially important population.

More from Scrip

Lilly’s Eloralintide Success Sets Bar For Amylin Rivals

 
• By Andrew McConaghie

The US pharma giant may have a best-in-class amylin agonist to go with incretin blockbuster Zepbound, but challengers could still go one better on safety and tolerability.

Bavarian Nordic Future Looks Bright Despite Failed Takeover Bid

 
• By Kevin Grogan

Even with Innosera's sweetened offers and a boardroom recommendation, the proposed acquisition could not clear the minimum 66.67% shareholder approval level.

Centessa’s Sleep Disorder Drug Shows Broad Potential But Faces Tough Competition

 
• By Sushmita Panda

Pivotal data next year will be key for the early-stage biotech as analysts remain divided on ORX750's potential.